Wang Dansong, Jin Dayong, Wu Zhaohan, Zou Weigou, Xu Dehua, Zheng Zhongcheng, Liu Xinyuan
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Yi Xue Za Zhi. 2002 Jun 25;82(12):844-7.
To study the therapeutic effects of human interleukin 10 (IL-10) gene transfer on severe acute pancreatitis (SAP) in rats.
Twenty healthy SD rats were injected intraperitoneally with SA liposome, SA liposome/pcDNA3 or SA liposome/pcDNA3-IL-10. Another twenty SD rats were randomly divided into five groups: rats in one group underwent laparotomy only (normal control), and SAP was induced in the other 4 groups induced by homogeneous injection of sodium taurocholate beneath the pancreatic capsule. Among the 4 SAP groups, one group did not receive any drugs, and liposomes, pcDNA3 or pcDNA3-IL-10 complexed with cationic liposomes were administered to the other groups. Drugs were administered by a single intraperitoneal injection thirty minutes after SAP had been induced. The levels of IL-10 in pancreas, liver and lungs were determined by ELISA kits. The level of serum amylase, histology, and tissue tumor necrosis factor (TNF) were assessed and mortality rate was observed in different groups for one week.
The levels of IL-10 in the pancreas, liver and lung 24 hours after IL-10 gene transfer, increased significantly (all > 350 pg/g), and then gradually decreased, however, the levels of IL-10 were still significantly higher that those in the control groups (P < 0.05) 96 hours later and decreased to normal in one week. The levels of IL-10 of transfer control group were not significantly different from those of the normal control group. The levels of IL-10 expression in pancreas, liver and lungs were increased significantly in the gene therapy group, compared with the SAP group. The serum amylase level was (4 300 +/- 700) U/L in normal control group, increased to (20 300 +/- 1 100) U/L 24 hour after SAP induction without a difference between the therapy control group and SAP group, and decreased to (6 800 +/- 700) U/L after IL-10 gene therapy (P < 0.05). The histological score of pancreas was 4.1 +/- 0.2 24 hours after the induction of SAP, and was 3.2 +/- 0.3 in the IL-10 therapy group. The level of TNF in pancreas, liver, and lungs 24 hours after the induction of SAP was significantly higher than that in normal control group (P < 0.05) and was not different from that in therapeutic control group. However, it was decreased markedly in IL-10 therapy group (P < 0.05). No rat in any group died within 2 days after onset. There was no difference of mortality between SAP group and therapeutic control group. The one-week mortality was 90% in the whole SAP group. The one-week mortality of IL-10 gene therapy group was 30 %, significantly lower than that in SAP group (P < 0.05). There was no significant difference in the therapeutic control groups and the SAP group. The values of relative risk of SAP group, SA liposome group, and pcDNA3 group were 12, 8, and 11 times higher than that of gene therapy group (P < 0.05).
Cationic liposome mediated pcDNA3-IL-10 gene therapy decreases significantly the severity and mortality of SAP.
研究人白细胞介素10(IL-10)基因转染对大鼠重症急性胰腺炎(SAP)的治疗作用。
将20只健康SD大鼠腹腔注射SA脂质体、SA脂质体/pcDNA3或SA脂质体/pcDNA3-IL-10。另外20只SD大鼠随机分为5组:一组仅行剖腹术(正常对照组),其他4组经胰包膜下均匀注射牛磺胆酸钠诱导产生SAP。在4个SAP组中,一组不给予任何药物,其他组分别给予脂质体、pcDNA3或与阳离子脂质体复合的pcDNA3-IL-10。在诱导产生SAP 30分钟后经腹腔单次注射给药。用ELISA试剂盒测定胰腺、肝脏和肺组织中IL-10的水平。评估不同组血清淀粉酶水平、组织学变化及组织肿瘤坏死因子(TNF)水平,并观察一周内的死亡率。
IL-10基因转染后24小时,胰腺、肝脏和肺组织中IL-10水平显著升高(均>350 pg/g),随后逐渐下降,但96小时后IL-10水平仍显著高于对照组(P<0.05),一周后降至正常。转染对照组IL-10水平与正常对照组无显著差异。与SAP组相比,基因治疗组胰腺、肝脏和肺组织中IL-10表达水平显著升高。正常对照组血清淀粉酶水平为(4300±700)U/L,SAP诱导后24小时升至(20300±1100)U/L,治疗对照组与SAP组无差异,IL-10基因治疗后降至(6800±700)U/L(P<0.05)。诱导产生SAP后24小时胰腺组织学评分为4.1±0.2,IL-10治疗组为3.2±0.3。诱导产生SAP后24小时,胰腺、肝脏和肺组织中TNF水平显著高于正常对照组(P<0.05),与治疗对照组无差异。但IL-10治疗组TNF水平显著降低(P<0.05)。发病后2天内各组均无大鼠死亡。SAP组与治疗对照组死亡率无差异。整个SAP组一周死亡率为90%。IL-10基因治疗组一周死亡率为30%,显著低于SAP组(P<0.05)。治疗对照组与SAP组无显著差异。SAP组、SA脂质体组和pcDNA组的相对危险度值比基因治疗组高12、8和11倍(P<0.05)。
阳离子脂质体介导的pcDNA3-IL-10基因治疗可显著降低SAP的严重程度和死亡率。